SCHEMBL20034028

SCHEMBL20034028

CC(C)c1csnc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HSP90AA1 P07900 1/20 0.40
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ALOX15 P16050 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166456 0.74 CYP11B1 (0.46) CYP11B1CYP11B2KDM4EL3MBTL1MEN1
SCHEMBL4587159 0.71 CYP11B1 (0.42) CYP11B1CYP11B2KDM4EMEN1KMT2A
SCHEMBL28020956 0.69 CYP11B1 (0.41) CYP11B1CYP11B2KDM4ELMNAL3MBTL1
SCHEMBL28013350 0.69 CYP11B1 (0.41) CYP11B1CYP11B2KDM4ELMNAMEN1
SCHEMBL28957794 0.69 CYP11B1 (0.41) CYP11B1CYP11B2KDM4ELMNAL3MBTL1
SCHEMBL27304439 0.69 CYP11B1 (0.41) CYP11B1CYP11B2KDM4ELMNAL3MBTL1
SCHEMBL6739617 0.69 ALDH1A1 (0.42) CYP11B1CYP11B2KDM4ELMNAMEN1
SCHEMBL27862904 0.69 ALDH1A1 (0.42) CYP11B1CYP11B2KDM4ELMNAL3MBTL1
SCHEMBL5154806 0.69 LMNA (0.45) CYP11B1CYP11B2KDM4ELMNAL3MBTL1
SCHEMBL20033981 0.69 GCGR (0.41) CYP11B1CYP11B2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-12-05 US disclosed
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues UNIV ARIZONA STATE (US) 2021-07-15 US disclosed
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-05-18 US disclosed
US-10626087-B2 Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same LOYOLA UNIVERSITY OF CHICAGO (US) 2020-04-21 US disclosed
US-20190084932-A1 INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-03-21 US disclosed
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2018-08-09 US disclosed
US-9941479-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084932-A1 INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME MGAM, NNMT, INMT CYP11B1 1978/4885CYP11B2 1791/4885KDM4E 1496/4885
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP CYP11B1 4262/4885CYP11B2 4377/4885KDM4E 4749/4885
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP CYP11B1 4262/4885CYP11B2 4377/4885KDM4E 4749/4885
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP CYP11B1 4262/4885CYP11B2 4377/4885KDM4E 4749/4885
US-10626087-B2 Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same MGAM, INMT, NNMT CYP11B1 1920/4885CYP11B2 2010/4885KDM4E 1290/4885
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP CYP11B1 4262/4885CYP11B2 4377/4885KDM4E 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.